Welcome to ECPC-European Cancer Patient Coalition

Established in 2003, the European Cancer Patient Coalition is the voice of the European cancer patient community, uniquely representing the interests of all cancer patient groups from the most common to the rare forms of cancer. We derive our mandate to speak with “one voice” for all cancer patients from our membership and our democratic structure. With its motto “Nothing about us without us!” ECPC represents 344 Members in 46 countries.

We need your support. Let’s all get involved and join forces for access to better patient experience, better cancer care, better public healthcare systems across Europe!

Latest News

  • EPAAC final deliverables available All the deliverable of the European Partnership for Action Against Cancer Joint Action (EPAAC) are now available on EPAAC website. Click here to download EPAAC deliverables   Download EPAAC deliverables produced in collaboration with ECPC: Boosting Innovation and Cooperation in European Cancer Control  REPORT of EPAAC WP7 Workshop on rare cancers    The European Partnership for Action Against Cancer (EPAAC) was launched ...
    Read more »
  • Report from the MIB Conference 2013 published The Report from the Melanoma Independent Board First Melanoma MIB Conference 2013 has been published on eCancer. The report, co-authored by ECPC President Francesco De Lorenzo, analyses the outcomes of the Melanoma Independent Board (MIB), which held its first conference from 21 to 22 October, 2013, in Rome, Italy. Like the MIB itself, the conference brought together specialists ...
    Read more »
  • Biosimilars: new publication from the European Commission How are biological medicines different from “classical” medicines? What is biosimilarity? Is there any difference in safety between the biosimilar and the reference product? What are the economic consequences of the use of biosimilars? Are biosimilars safe? The latest publication from the European Commission Directorate General for Industry replies of these and more questions related to biosimilars. The document, entitled “What you ...
    Read more »